Elevance Health price target raised to $404 from $385 at Barclays

Barclays analyst Andrew Mok raised the firm’s price target on Elevance Health (ELV) to $404 from $385 and keeps an Overweight rating on the shares. The firm sees managed care stocks benefiting in 2026 from the prospects of margin expansion and rotation away from artificial intelligence-related stocks toward “de-rated underperformers.”